Key takeaways
- Two large meta-analyses covering over 2.1 million pregnancies found no link between early GLP-1 exposure and birth defects.
What happened
Two comprehensive systematic reviews and meta-analyses, representing more than 2.1 million pregnancies, have found that exposure to GLP-1 receptor agonists around the time of conception or during early pregnancy does not appear to increase the risk of major congenital anomalies or other serious perinatal complications. These reassuring findings, published in the journal Med and presented at the European Association for the Study of Diabetes (EASD) annual meeting, provide the largest clinical evaluation to date of early fetal exposure to blockbusters like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). However, researchers from both teams stress that these results should not be interpreted as an endorsement for continuing the medications during pregnancy, and existing medical guidance to stop taking them before conceiving remains unchanged.
Why it matters
This clinical development provides crucial, much-needed reassurance for women of childbearing age in the United States, particularly those utilizing cash-pay online telehealth platforms. Because weight loss from GLP-1 therapy can restore natural ovulation and boost fertility in patients with polycystic ovary syndrome (PCOS) or obesity, "accidental" early pregnancies are increasingly common among patients taking these medications.
While the official manufacturer labeling for Wegovy and Zepbound recommends stopping the injections at least two months prior to a planned pregnancy, real-world adherence can lag behind clinical guidelines. For patients who suddenly discover they are pregnant while taking a weekly GLP-1, this data lowers the immediate anxiety regarding birth defects or major pregnancy complications, even as they take immediate steps to halt the medication.
What the data says
The clinical evidence comes from two distinct, major publications:
- *The Med Study:* Led by Dr. Asma Khalil of City St George's University of London, this systematic review and meta-analysis pooled data from 10 studies covering more than 2.1 million pregnancies. It found no detectable increase in miscarriage, intrauterine death, congenital anomalies, preterm birth, gestational diabetes, small- or large-for-gestational-age infants, or excessive gestational weight gain among women exposed to GLP-1s during the periconceptional period. Notably, the study observed a lower pooled estimate for preeclampsia (OR 0.87), though researchers urged caution due to the limited dataset for that specific outcome.
- *The EASD / Lancet Study:* Led by Dr. Claire Meek of the University of Leicester, this review analyzed data from over 40,000 women (primarily with type 2 diabetes). It confirmed no increased risk of congenital anomalies when GLP-1s were discontinued during the first trimester (RR 1.02). While there was a statistical rise in early pregnancy loss under 22 weeks (RR 1.31), the authors noted this was difficult to interpret because the largest contributing dataset combined natural miscarriages and voluntary medical terminations together.
Despite the broadly reassuring results, both research teams pointed out that the data does not establish absolute safety due to differences in how drug exposure was defined across historical records and the potential for residual confounding variables.
How it compares
For telehealth buyers comparing GLP-1 options, navigating the transition off medication is a critical piece of the treatment journey. Currently, brand-name GLP-1 medications are highly expensive for cash-paying patients without insurance coverage. Out-of-pocket costs for brand Wegovy average $1,350 per month, while Zepbound costs upwards of $1,000 per month.
Because of these steep prices, many patients choose compounded semaglutide or compounded tirzepatide through online clinics. If you are using a telehealth platform to access compounded alternatives, the same safety rules apply: the active ingredients are molecularly similar to the brand names, meaning therapy must still be paused during pregnancy.
When planning a pregnancy, stopping treatment means losing the appetite-suppressing benefits of the drug. Telehealth patients must prepare for the clinical math of weight maintenance without pharmacological assistance. Patients should look to compare medical weight loss providers to see which platforms offer comprehensive nutritional support and tapering strategies, rather than just writing prescriptions. Some budget providers offer simple medication-only subscriptions, but platforms with comprehensive care can help you transition safely off the drug when you decide to start a family.
How this fits the bigger picture
This study addresses a major gap in patient safety that has grown alongside the direct-to-consumer medical weight-loss market. As telehealth platforms have made access to these medications faster and easier, the demographic of patients on GLP-1s has shifted significantly toward younger women.
This shift is occurring at a time when employers are scaling back insurance coverage due to rising drug costs, as explored in our coverage on how employer benefit overhauls are driving buyers to cash telehealth. As more women pay out of pocket, they may bypass traditional OB-GYN consultations in favor of quick online prescriptions, making clear, accessible clinical data about early pregnancy exposure incredibly vital.
Furthermore, halting a GLP-1 suddenly can have other health implications. While stopping the drug is absolutely necessary upon learning of a pregnancy, doing so abruptly outside of pregnancy carries documented cardiovascular and metabolic risks. For instance, our report on how stopping GLP-1s raises heart attack and stroke risks highlights the compounding health risks patients face when they experience gaps in therapy. For women planning a family, a structured clinical plan with their primary care physician is essential to manage the cardiovascular and metabolic transition safely.
What happens next
Following these findings, Dr. Meek and her colleagues have crafted the first international consensus statement regarding GLP-1 use before, during, and after pregnancy for women with diabetes. Moving forward, clinical societies are expected to use this consensus to establish clearer preconception targets and educational strategies to help women understand when and how to stop taking these medications safely.
Additionally, while there is interest in using GLP-1s to manage gestational diabetes or type 1 diabetes during pregnancy, clinical evidence remains scarce. Future clinical trials and real-world registries will need to collect proactive data on lactation and active use during the second and third trimesters before any regulatory bodies like the FDA consider altering the current contraindications for pregnancy.
For now, the medical consensus remains absolute: if you are planning to become pregnant, you should discontinue your GLP-1 medication at least two months beforehand, and use reliable contraception while actively on the drug.
Disclaimer: CompareRx does not provide medical advice. If you are taking a GLP-1 medication and are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider immediately to discuss a safe treatment plan.